aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St futures muted as oil tops $100 for first time since July
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
aTyr Pharma (LIFE) PT Lowered to $1 at BMO Capital
August 15, 2018 7:29 AM EDTBMO Capital analyst Matthew Luchini lowered the price target on aTyr Pharma (NASDAQ: LIFE) to $1.00 (from $2.00) while maintaining a Market Perform rating.
... MoreaTyr Pharma (LIFE) Misses Q2 EPS by 2c
August 14, 2018 4:23 PM EDTaTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33).
We have made important advancements in the development of our lead product candidate, ATYR1923, during the recent months, said Sanjay Shukla, M.D., M.S., President and CEO of aTyr.... More
